Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLUTION: Vortioxetine vs Venlafaxine XR in Asian MDD
NCT01571453Phase 3Completed
- Sponsor
- Lundbeck
- Start
- May 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Lundbeck. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Total Score at 8 weeks. Started May 2012; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01571453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571453.